GEN Exclusives

More »

GEN News Highlights

More »
Feb 4, 2009

Private Equity Firm to Take Over PharmaNet for $100M

  • JLL Partners has agreed to acquire PharmaNet Development Group for about $100 million. JLL will pay $5.00 per share, more than three times PharmaNet’s closing price on February 2, the day before the transaction was made public. PharmaNet’s stock jumped to over $4 during trading yesterday.

    The transaction will be financed by a $250 million equity commitment from JLL, which includes the necessary funds to retire the $144 million principal amount of the company's outstanding convertible notes. The parties expect the tender offer to close by the end of this quarter.

    PharmaNet provides a range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The company offers early- and late-stage consulting, Phase I studies and bioanalytical analyses, as well as Phase II, III, and IV clinical development programs. It has approximately 2,500 employees and 41 facilities throughout the world.

    ---

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »